Stop the Sag: How Hollywood Is Battling 'Ozempic Body'
Surgeons like New York-based Macrene Alexiades have made a specialty of it. 'I have successfully treated and reversed GLP-1 sagginess in my patients with radiofrequency treatments for skin laxity reduction, combined with PRP plus artful strategic filler placement to restore key areas of atrophy,' Alexiades tells THR. 'Usually two treatment sessions, a month apart, is enough to achieve a full correction and restoration.'
More from The Hollywood Reporter
Knives Out: Celebrities Reveal Plastic Surgery Secrets - But One Procedure Still Taboo
How Soon Before a Robot Performs Your Facelift?
The Facelift Gets a Facelift: Hollywood's Favorite Procedure Is Back
Dermatologist Simon Ourian, meanwhile, focuses 'on restoring collagen and muscle mass, which are often depleted during rapid weight loss.' Says Dr. Ourian, 'We use our proprietary [hyaluronic acid-based] Neustem regenerative protocol to rebuild structural support, enhance muscle tone, and restore vitality to the face and body without the risk of overfilling. For the body, we combine regenerative solutions with energy-based skin tightening and contouring to address loose skin and improve definition in areas like the abdomen, arms and thighs.'
Paul Jarrod Frank recommends second-generation scarless skin removal — a technique known as Ellacor fractional micro-coring — to treat crepey skin on the face, neck, arms, abdomen, legs and back. 'Unlike microneedling, which punches holes in the skin and delivers heat, Ellacor punches holes and literally cores out just under a millimeter of skin, done thousands of times over each area to remove a significant percentage with each treatment,' the dermatologist explains. 'The advantage is that you are removing, lifting and tightening skin without having to do a more aggressive surgical intervention. Holes close in 24 hours, with full recovery in five days.'
Beverly Hills dermatologist Rhonda Rand (Angelina Jolie is a longtime client) leans into a combo of facial fillers, plus 'radiofrequency microneedling to help tighten the skin and high-intensity focused ultrasound to stimulate collagen at deeper levels.' She tells THR, 'In severe cases of facial wasting, even a facelift would be appropriate. When the skin is sagging so much, noninvasive procedures may not be enough.'
GLP-1s have also ushered in a new wave of skin care products. Chicago-based plastic surgeon Julius Few (who has collaborated with Gwyneth Paltrow for Goop) recently added a $300 topical DermaReverse serum to his product line 'designed specifically for GLP-1 users experiencing GLP Face' as well as a $195 Skin Tightening + SPF 30 with Dermatight to target sagging and laxity on the body. Image Skincare, which has a strong Hollywood following, has introduced $134 Vol.U.Lift, developed by the company's plastic surgeon co-founder to address volume loss, sagging and other side effects of GLP-1 usage.
Launching a whole new industry? Add it to that list of miraculous effects.
This story appeared in the July 30 issue of The Hollywood Reporter magazine. Click here to subscribe.
Best of The Hollywood Reporter
Seeing Double? 25 Pairs of Celebrities Who Look Nearly Identical
From 'Lady in the Lake' to 'It Ends With Us': 29 New and Upcoming Book Adaptations in 2024
Meet the Superstars Who Glam Up Hollywood's A-List
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 minutes ago
- Yahoo
Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition
On Tuesday, the eye care company Alcon Plc (NYSE:ALC) agreed to acquire STAAR Surgical Company (NASDAQ:STAA), the manufacturer of the implantable collamer lens (ICL). The acquisition includes the EVO family of lenses (EVO ICL) for vision correction for patients with moderate to high myopia (nearsightedness), with or without astigmatism. Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, which represents approximately a 59% premium to STAAR's 90-day Volume Weighted Average Price (VWAP) and a 51% premium to the closing price of STAAR common stock on August 4, transaction represents a total equity value of approximately $1.5 billion. Alcon intends to finance the transaction by issuing short- and long-term credit facilities. The transaction is anticipated to close in approximately six to 12 months and is expected to be accretive to earnings in year two. 'With the number of high myopes rising globally, the acquisition of STAAR enhances our ability to offer a leading surgical vision correction solution for those who are not ideal candidates for other refractive surgeries such as LASIK,' said David Endicott, CEO of Alcon. An estimated 50% of the world will be myopic by 2050, and today, nearly 500 million people are considered high myopes. The EVO family of ICLs are implanted between the iris (the colored part of the eye) and the natural crystalline lens during a procedure that does not remove corneal tissue. This move follows Alcon's recent announcement in July regarding its intention to acquire LumiThera, Inc. and its Photobiomodulation (PBM) Device for dry age-related macular degeneration (AMD). Data from the LIGHTSITE I, II, and III clinical trials consistently showed that PBM treatments provide visual acuity improvement with no treatment-related serious adverse events reported. PBM received FDA de novo market authorization in November 2024 and CE Mark in November 2018. PBM is available in Europe, Latin America, Singapore, the U.K., and the U.S. The transaction does not include the acquisition of AdaptDx and Nova/Diopsys diagnostic devices, which will be separated and spun off to LumiThera's shareholders before Alcon's acquisition and will continue to be marketed and sold by the LumiThera spin-off. Alcon and LumiThera anticipate the acquisition to be completed in the third quarter of 2025. Price Action: ALC stock is trading lower by 1.17% to $86.79 premarket, and STAA stock is trading higher by 44.9% to $26.78 at last check Tuesday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? STAAR SURGICAL (STAA): Free Stock Analysis Report This article Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
33 minutes ago
- Yahoo
Digital health company eMed taps former X boss Linda Yaccarino as CEO
(Reuters) - Digital health platform eMed Population Health said on Tuesday it has appointed Linda Yaccarino, the former CEO of social media site X, as its chief executive officer. The online weight management company's digital platform provides at-home diagnostics, proctor-led screenings, physician-guided prescribing for patients with obesity and type 2 diabetes. Yaccarino, one of Elon Musk's top deputies, stepped down from her role at the social media site in July, in a surprise move just months after the platform was acquired by the billionaire's AI startup, xAI.
Yahoo
33 minutes ago
- Yahoo
Annual spending on specialty drugs continues to increase but at a slower pace than prior years, driven in part by biosimilar adoption.
DALLAS, August 05, 2025--(BUSINESS WIRE)--Pharmaceutical Strategies Group ("PSG"), an EPIC company, released the Artemetrx State of Specialty Spend and Trend report. This annual report provides a comprehensive analysis based on real world data of utilization of specialty medications across both pharmacy and medical benefits. This year's report revealed per member per year specialty drug cost increased from $1,333 in 2023 to $1,641 in 2024. However, specialty drug trend decreased to 9.6% in 2024 on a gross cost basis, a decline from 14.4% in 2023. Notably, cost per claim was meaningfully less of a contributor to trend this year versus recent years. "The data reveals a compelling story regarding what is happening with specialty drugs. Overall costs continue to increase for healthcare payers, but what is driving that cost is changing," stated Morgan Lee, PhD, Senior Director of Research & Strategy at PSG. "Adoption of Humira biosimilars helped pull specialty trend down this year, which is evident throughout the report," Lee added. While Humira continued its multi-year reign as the top specialty drug in terms of overall spend, this popular drug experienced negative utilization and cost per claim trends driven by the adoption of biosimilars. "In 2024, we saw the benefit to healthcare payers of Humira biosimilars as PBMs shifted strategies to take advantage of competition in the market," observed Renee Rayburg, RPh, Vice President of Clinical Strategy at PSG. "We expect to see faster adoption of Stelara biosimilars, which entered the market early this year. However, we're also seeing a push to move patients from these drugs to other brand drugs that do not have biosimilar competition." The Artemetrx State of Specialty Spend and Trend Report reflects PSG's commitment to providing data-driven insights regarding the management of and opportunities to optimize specialty medications. The complimentary report can be downloaded here. Additional findings covered in the report include: The percentage of members utilizing a specialty drug increased (4.7%), while average specialty claims per utilizer was steady (5.9) The shift of specialty drug spending to the pharmacy benefit continued The top three categories for specialty drug spend remained unchanged: Inflammatory Disorder, Oncology, Multiple Sclerosis PSG will host a webinar on August 13th, at 1:00 ET to discuss how this report can shape a roadmap for proactive specialty spend control. Registration is available online. About Pharmaceutical Strategies Group (PSG) Pharmaceutical Strategies Group, an EPIC company, relentlessly advocates for clients as they navigate complex and ever-changing drug cost management challenges. PSG is an independent consultant, empowering healthcare payers to optimize their pharmacy program. As a strategic partner, PSG helps clients by providing industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year. About Artemetrx® Artemetrx is a proprietary SaaS platform developed by Pharmaceutical Strategies Group, an EPIC company. As a revolutionary technology solution integrating pharmacy and medical claims data for specialty drug cost management, Artemetrx provides market-leading specialty drug insights to payers. It delivers unparalleled intelligence and line-of-sight into serious challenges perpetuating out-of-control drug costs and compromised patient outcomes. PSG's innovative drug management solutions, including Artemetrx, deliver actionable insights with exceptional financial and clinical value. PSG functions as a strategic partner through industry-leading intelligence and technologies to realize billions of dollars in drug cost savings for clients every year. View source version on Contacts Artemetrx Business Development Travis Media Contact Gregory FCA For Pharmaceutical Strategies GroupKara Lesterepic@ Sign in to access your portfolio